Last Updated on December 31, 2023 by The Health Master
The US Food and Drug Administration (USFDA) has approved Lupin’s Abbreviated New Drug Application (ANDA), Mirabegron Extended-Release Tablets, 25 mg, and 50 mg.
This approval is to market a generic equivalent of Myrbetriq extended-release tablets, 25 mg, and 50 mg, of Astellas Pharma Global Development, according to a statement from Lupin.
The product will be manufactured at Lupin’s facility in Nagpur, the statement added.
USFDA gives nod for this generic non-steroidal anti-inflammatory drug
USFDA approves Intravenous therapy for hearing loss
USFDA approves Terlipressin for injection to treat Kidney function
USFDA gives tentative approval for Sugammadex Injection
USFDA gives approval for Lenalidomide capsules
USFDA gives final approval for Cariprazine capsules
State FDAs of these states to be strengthened soon
Drug recall: Acyclovir Sodium Injection recalled due to this reason
FDA J&K suspended licenses of Medicals Stores & Pharma Dealers
J & J appeals to Maharashtra FDA minister to revoke cancellation of license
IPGA Tamil Nadu Branch Celebrates World Pharmacists Day
Changing the Regulations for Class A Medical Devices and its Impact
Govt plan to ban Codeine based cough syrups opposed by Pharma companies
Cancer medicines may get cheaper
Pharmacists – The Doctors behind the screens
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
